{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T03:21:51Z","timestamp":1787628111194,"version":"build-2736575974"},"reference-count":74,"publisher":"Informa UK Limited","issue":"19","license":[{"start":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T00:00:00Z","timestamp":1712707200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Gilead Sciences Japan"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncology"],"published-print":{"date-parts":[[2024,6,14]]},"DOI":"10.2217\/fon-2023-1114","type":"journal-article","created":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T13:34:06Z","timestamp":1712756046000},"page":"1333-1349","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":8,"title":["Cost\u2013effectiveness analysis 3L of axicabtagene ciloleucel vs tisagenlecleucel and lisocabtagene maraleucel in Japan"],"prefix":"10.1080","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8412-8778","authenticated-orcid":false,"given":"Saaya","family":"Tsutsu\u00e9","sequence":"first","affiliation":[{"name":"Gilead Sciences Japan,1-9-2 Marunouchi, Chiyoda-ku, Tokyo, 100-6616, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Makita","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroya","family":"Asou","sequence":"additional","affiliation":[{"name":"Gilead Sciences Japan,1-9-2 Marunouchi, Chiyoda-ku, Tokyo, 100-6616, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Matsuda","sequence":"additional","affiliation":[{"name":"IQVIA Solutions, Japan, 4-10-18 Takanawa Minato-ku, Tokyo, 108-0074, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiko","family":"Yamaura","sequence":"additional","affiliation":[{"name":"IQVIA Solutions, Japan, 4-10-18 Takanawa Minato-ku, Tokyo, 108-0074, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd D","family":"Taylor","sequence":"additional","affiliation":[{"name":"IQVIA Solutions, Japan, 4-10-18 Takanawa Minato-ku, Tokyo, 108-0074, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,4,10]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15926"},{"key":"e_1_3_5_5_1","unstructured":"Statistics Bureau of Japan. 2020 Summary of the results and statistical tables: Ministry of Internal Affairs and Communications. (2021) www.stat.go.jp\/english\/data\/kokusei\/2020\/summary.html"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-018-2430-6"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12659"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1827.2007.02207.x"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0237509"},{"key":"e_1_3_5_11_1","unstructured":"Food and Drug Administration (FDA). Drugs@FDA: FDA-Approved Drugs. (2023). www.accessdata.fda.gov\/scripts\/cder\/daf\/"},{"key":"e_1_3_5_12_1","unstructured":"Pharmaceuticals and Medical ZDevices Agency (PMDA). [List of approved cell and gene therapy products]. (2023). www.pmda.go.jp\/review-services\/drug-reviews\/review-information\/ctp\/0004.html"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2016.1.366"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.213"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015789"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)31366-0"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011994"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115304"},{"key":"e_1_3_5_21_1","unstructured":"Center for Outcomes Research and Economic Evaluation for Health (C2H). Target items and results after full-scale introduction (2019.4-): National Institute of Public Health. (2023). https:\/\/c2h.niph.go.jp\/en\/results\/item.html"},{"key":"e_1_3_5_22_1","unstructured":"Center for Outcomes Research and Economic Evaluation for Health (C2H). [C2H1902] tisagenlecleucel (Kymriah): National Institute of Public Health. (2021). https:\/\/c2h.niph.go.jp\/results\/C2H1902.html"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.20683\/jniph.70.1_22"},{"key":"e_1_3_5_24_1","unstructured":"Ministry of Health Labour and Welfare (MHLW). [List of Items Listed in the NHI Drug Price Standards and Information on Generic Drugs (Effective October 1 2023)]. (2023). www.mhlw.go.jp\/topics\/2023\/04\/tp20230401-01.html"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2018.1529674"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.0035"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-022-07041-2"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2022.2065787"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2021.1901721"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-022-01169-z"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02188-0"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030538"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2021.11.1351"},{"key":"e_1_3_5_34_1","unstructured":"Phillippo D Ades T Dias S et al. NICE DSU Technical Support Document 18: methods for population-adjusted indirect comparisons in submissions to NICE: NICE Decision Support Unit University of Bristol \u2013 Explore Bristol Research. (2016). https:\/\/research-information.bris.ac.uk\/ws\/portalfiles\/portal\/94868463\/Population_adjustment_TSD_FINAL.pdf"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.06.008"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2022.2113526"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-0400"},{"key":"e_1_3_5_38_1","unstructured":"Ministry of Health Labour and Welfare (MHLW). [Medical Fee Related Information]. (2023). www.mhlw.go.jp\/english\/wp\/wp-hw3\/02.html"},{"key":"e_1_3_5_39_1","unstructured":"Ministry of Health Labour and Welfare (MHLW). [Optimal Clinical Use Guidelines: Axicabtagene Ciloleucel (revised 2022)]. (2021). www.pmda.go.jp\/files\/000249516.pdf"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17673"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18209"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4820"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-021-02033-4"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.03.005"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0325-z"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1390230"},{"key":"e_1_3_5_47_1","unstructured":"Center for Outcomes Research and Economic Evaluation for Health (C2H). Guideline for Preparing Cost\u2013effectiveness Evaluation to the Central Social Insurance Medical Council Ver.3: National Institute of Public Health. (2022) https:\/\/c2h.niph.go.jp\/tools\/guideline\/guideline_en.pdf"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02079"},{"key":"e_1_3_5_49_1","unstructured":"Woods B Sideris E Palmer S et al. NICE DSU TECHNICAL SUPPORT DOCUMENT 19: PARTITIONED SURVIVAL ANALYSIS FOR DECISION MODELLING IN HEALTH CARE: A CRITICAL REVIEW Sheffield: Decision Support Unit ScHARR University of Sheffield. (2017). www.sheffield.ac.uk\/sites\/default\/files\/2022-02\/TSD19-Partitioned-Survival-Analysis-final-report.pdf"},{"key":"e_1_3_5_50_1","unstructured":"Ministry of Health Labour and Welfare (MHLW). [Summary of the 23rd Life Table (Complete Life Table)]. (2023). www.mhlw.go.jp\/toukei\/saikin\/hw\/life\/23th\/index.html"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-12-9"},{"issue":"1","key":"e_1_3_5_52_1","first-page":"48","article-title":"[CAR-T cell therapy: practice and challenges from a transfusion department nurse's perspective] [review]","volume":"12","author":"Takagi N","year":"2023","unstructured":"Takagi N. [CAR-T cell therapy: practice and challenges from a transfusion department nurse's perspective] [review]. Japanese J. Transplant. Cell. Ther. 2023;12(1):48\u201358.","journal-title":"Japanese J. Transplant. Cell. Ther."},{"key":"e_1_3_5_53_1","unstructured":"Vision MD. MDV Database Overview . (2023). https:\/\/en.mdv.co.jp\/ebm\/about-mdv-database\/mdv-database-overview\/"},{"key":"e_1_3_5_54_1","unstructured":"Survey of Japanese databases in Japan available for clinical\/pharmacoepidemiology. Survey of Japanese databases in Japan available for clinical\/pharmacoepidemiology: Japanese Society for Pharmacoepidemiology. (2023). www.jspe.jp\/committee\/020\/0210\/"},{"key":"e_1_3_5_55_1","unstructured":"Bank of Japan. Bank of Japan. [The reference foreign exchange rates for Japanese currency and arbitrated foreign exchange rates of foreign currencies to Japanese currency]. (2023). www.boj.or.jp\/about\/services\/tame\/tame_rate\/kijun\/index.htm"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2020.1804392"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-11-817775"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003848"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.13552"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00754-1"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009117"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02444-x"},{"key":"e_1_3_5_63_1","unstructured":"NICE (National Institute for Health and Care Excellence). Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies. 2023 [cited September 23 2023]. Available from: www.nice.org.uk\/guidance\/ta872"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.10.005"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1097\/hs9.0000000000000188"},{"issue":"6","key":"e_1_3_5_66_1","first-page":"625","article-title":"[Guideline for economic evaluation of healthcare technologies in Japan] [Commentary\/Special feature]","volume":"62","author":"Fukuda T","year":"2013","unstructured":"Fukuda T, Shiroiwa T, Ikeda S et al. [Guideline for economic evaluation of healthcare technologies in Japan] [Commentary\/Special feature]. J. National Institute Public Health 2013;62(6):625\u2013640.","journal-title":"J. National Institute Public Health"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000736"},{"key":"e_1_3_5_68_1","unstructured":"Ministry of Health Labour and Welfare. [Calculation of reimbursement price for regenerative medicine products: lisocabtagene maraleucel]. 2021 [cited October 9 2023]. Available from: www.mhlw.go.jp\/content\/12404000\/000777799.pdf"},{"key":"e_1_3_5_69_1","unstructured":"Ministry of Health Labour and Welfare. [Calculation of Reimbursement Price for Regenerative Medicine Products: tisagenlecleucel]. 2019 [cited October 9 2023]. Available from: www.mhlw.go.jp\/content\/12404000\/000508918.pdf"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116133"},{"key":"e_1_3_5_71_1","doi-asserted-by":"crossref","unstructured":"Kelkar AH Jacobson CA Abel GA et al. Cost\u2013effectiveness of CD19 Chimeric Antigen Receptor T Cell Therapy Versus Autologous Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma in First Relapse. 2022 Tandem Meetings| Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR: Tandem Meetings. 2022 [cited October 19 2023]. Available from: https:\/\/tandem.confex.com\/tandem\/2022\/meetingapp.cgi\/Paper\/19877","DOI":"10.1016\/S2666-6367(22)00587-5"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.45956"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.08.010"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011793"},{"key":"e_1_3_5_75_1","unstructured":"The Dental and Pharmaceutical Benefits Agency. [Health economic assessment of the first CAR-T cell therapy Yescarta]: The Dental and Pharmaceutical Benefits Agency. 2018 [cited October 19 2023]. Available from: www.tlv.se\/press\/nyheter\/arkiv\/2018-11-15-halsoekonomisk-bedomning-av-den-forsta-car-t-cellbehandlingen.html"},{"key":"e_1_3_5_76_1","unstructured":"Aronsson M Ling C Stevenson A et al. Submission Process and Requirements of Nordic Health Technology Assessment Authorities for Hospital Drugs: Implications for Market Access Strategy. 2019 [cited October 9 2023]. Available from: www.ispor.org\/docs\/default-source\/euro2019\/ohisporeuarronsondocusourceposter-pdf.pdf?sfvrsn=71e5e859_0"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2023-1114","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T22:26:48Z","timestamp":1744064808000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2023-1114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,10]]},"references-count":74,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2024,6,14]]}},"alternative-id":["10.2217\/fon-2023-1114"],"URL":"https:\/\/doi.org\/10.2217\/fon-2023-1114","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,10]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-12-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}